Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, China.
PLoS One. 2013;8(2):e57830. doi: 10.1371/journal.pone.0057830. Epub 2013 Feb 28.
Aberrant expression of C-X-C motif chemokine 5 (CXCL5) contributes to the progression of various cancers. This study analyzed the clinical significance of serum CXCL5 (sCXCL5) levels of nasopharyngeal carcinoma (NPC) patients, with the goal of building a novel prognostic score model.
Serum samples were collected prior to treatment from 290 NPC patients for the detection of sCXCL5 with ELISA. Half of the patients (n = 145) were randomly assigned to the training set to generate the sCXCL5 cutoff point using receiver operator characteristic (ROC) analysis, while the other half (n = 145) were assigned to the testing set for validation. Associations between sCXCL5 levels and clinical characteristics were analyzed. A prognostic score model was built using independent predictors derived from multivariate analysis. A concordance index (C-Index) was used to evaluate prognostic ability.
The sCXCL5 cutoff point was 0.805 ng/ml. Sex, age, histology, T classification, clinical classification and local recurrence were not associated with sCXCL5 levels. However, sCXCL5 levels were positively associated with N classification, distant metastasis and disease progression (P<0.05). A high sCXCL5 level predicted poor 6-year overall survival (OS), poor 6-year distant metastasis-free survival (DMFS), and poor 6-year progression-free survival (PFS). A prognostic score model was subsequently constructed based on sCXCL5 levels and clinical classification (C-C model), which are independent predictors of OS, DMFS, and PFS, as confirmed by the multivariate analysis. Furthermore, this novel model successfully divided the patients into four risk subgroups in the training set, the testing set and the entire set of patients. The C-Indices were 0.751 and 0.762 for the training set and the testing set, respectively.
sCXCL5 level was determined to be an independent prognostic factor for NPC patients. The novel statistical C-C model, which includes sCXCL5 levels and clinical classification, could be helpful in predicting the prognosis of NPC patients.
C-X-C 基序趋化因子 5(CXCL5)的异常表达促进了多种癌症的进展。本研究分析了鼻咽癌(NPC)患者血清 CXCL5(sCXCL5)水平的临床意义,旨在构建一种新的预后评分模型。
采集 290 例 NPC 患者治疗前的血清样本,用酶联免疫吸附试验(ELISA)检测 sCXCL5。将患者随机分为两组,其中一半(n=145)用于训练集,通过受试者工作特征(ROC)分析确定 sCXCL5 截断值;另一半(n=145)用于测试集进行验证。分析 sCXCL5 水平与临床特征的相关性。利用多因素分析得到的独立预测因素构建预后评分模型。采用一致性指数(C-Index)评估预后能力。
sCXCL5 截断值为 0.805ng/ml。性别、年龄、组织学、T 分期、临床分期和局部复发与 sCXCL5 水平无关。然而,sCXCL5 水平与 N 分期、远处转移和疾病进展呈正相关(P<0.05)。高 sCXCL5 水平预示着患者 6 年总生存率(OS)、6 年无远处转移生存率(DMFS)和 6 年无进展生存率(PFS)较差。随后基于 sCXCL5 水平和临床分期(C-C 模型)构建了一个预后评分模型,该模型是 OS、DMFS 和 PFS 的独立预测因素,这一点在多因素分析中得到了证实。此外,该新模型在训练集、测试集和全组患者中成功将患者分为四个风险亚组。C-Index 在训练集和测试集分别为 0.751 和 0.762。
sCXCL5 水平是 NPC 患者的独立预后因素。包含 sCXCL5 水平和临床分期的新型统计 C-C 模型有助于预测 NPC 患者的预后。